Epidemiology of hepatitis C in Europe

Digestive and Liver Disease

Volumn 46, Issue S5, 2014, Pages S158-S164

  Negro, Francesco ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Epidemiology; Hepatitis C; Migrants; People who inject drugs; Prisoners

Indexed keywords

BLOODBORNE BACTERIUM; CZECH REPUBLIC; DECOMPENSATED LIVER CIRRHOSIS; ENDOSCOPY; FOLLOW UP; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN TRAFFICKING; INFECTION; INFECTION RISK; LIVER CELL CARCINOMA; MEDICAL PRACTICE; PREVALENCE; PUBLIC HEALTH; REVIEW; RISK FACTOR; RNA SEQUENCE; VIRUS TRANSMISSION; EUROPE; HEPATITIS C, CHRONIC; MORTALITY;

EUROPE; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; MORTALITY; RISK FACTORS;

EID: 84919342971     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.09.023     Document Type: Review

References (89)

1. Davis G.L., Alter M.J., El-Serag H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513-521. 521.e1-6.
2. Razavi H., Waked I., Sarrazin C., et al. The present and future disease burden of hepatitis C virus with today's treatment paradigm. Journal of Viral Hepatitis 2014, 21(Suppl. 1):34-59.
3. Perz J.F., Armstrong G.L., Farrington L.A., et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology 2006, 45:529-538.
4. Lee M.H., Yang H.I., Lu S.N., et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. Journal of Infectious Diseases 2012, 206:469-477.
5. van der Meer A.J., Veldt B.J., Feld J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Journal of the American Medical Association 2012, 308:2584-2593.
6. Ly K.N., Xing J., Klevens R.M., et al. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clinical Infectious Diseases 2014, 58:40-49.
7. Cowie B.C., Allard N., MacLachlan J.H. European responses in focus: comparing viral hepatitis and HIV related deaths in Europe 1990-2001 in the Global Burden of Disease Study 2010. 49th Annual meeting of the European association for the study of the liver 2014, abstract #86.
8. Mahajan R., Xing J., Liu S.J., et al. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clinical Infectious Diseases 2014, 58:1055-1061.
9. Hsu Y.C., Lin J.T., Ho H.J., et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014, 59:1293-1302.
10. Hsu C.S., Kao J.H., Chao Y.C., et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Alimentary Pharmacology and Therapeutics 2013, 38:415-423.
11. Mohd Hanafiah K., Groeger J., Flaxman A.D., et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57:1333-1342.
12. Cornberg M., Razavi H.A., Alberti A., et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver International 2011, 31(Suppl. 2):30-60.
13. Blachier M., Leleu H., Peck-Radosavljevic M., et al. The burden of liver disease in Europe: a review of available epidemiological data. Journal of Hepatology 2013, 58:593-608.
14. Bruggmann P., Berg T., Øvrehus A., et al. Historical epidemiology of hepatitis C virus (HCV) in select countries. Journal of Viral Hepatitis 2014, 21(Suppl. 1):5-33.
15. Garcia-Fulgueiras A., Garcia-Pina R., Morant C., et al. Burden of disease related to hepatitis C and hepatitis B in Spain: a methodological challenge of an unfolding health problem. Journal of Viral Hepatitis 2011, 18:e453-e460.
16. Marcellin P., Pequignot F., Delarocque-Astagneau E., et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. Journal of Hepatology 2008, 48:200-207.
17. Muhlberger N., Schwarzer R., Lettmeier B., et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009, 9:34.
18. http://www.mortality.org/.
19. Donahue J.G., Muñoz A., Ness P.M., et al. The declining risk of post-transfusion hepatitis C virus infection. New England Journal of Medicine 1992, 327:369-373.
20. Pomper G.J., Wu Y., Snyder E.L. Risks of transfusion-transmitted infections: 2003. Current Opinion in Hematology 2003, 10:412-418.
21. Mauser-Bunschoten E.P., Bresters D., van Drimmelen A.A., et al. Hepatitis C infection and viremia in Dutch hemophilia patients. Journal of Medical Virology 1995, 45:241-246.
22. Pipe S. Consideration in hemophilia therapy selection. Seminars in Hematology 2006, 43(Suppl. 3):S23-S27.
23. Chiaramonte M., Stroffolini T., Lorenzoni U., et al. Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy. Journal of Hepatology 1996, 24:129-134.
24. de Lédinghen V., Trimoulet P., Mannant P.R., et al. Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years). Journal of Hepatology 2007, 46:19-25.
25. Karmochkine M., Carrat F., Dos Santos O., et al. A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. Journal of Viral Hepatitis 2006, 13:775-782.
26. Quer J., Esteban J.I., Sánchez J.M., et al. Nosocomial transmission of hepatitis C virus during contrast-enhanced computed tomography scanning. European Journal of Gastroenterology and Hepatology 2008, 20:73-78.
27. González-Candelas F., Guiral S., Carbó R., et al. Patient-to-patient transmission of hepatitis C virus (HCV) during colonoscopy diagnosis. Virology Journal 2010, 7:217.
28. Saludes V., Esteve M., Casas I., et al. Hepatitis C virus transmission during colonoscopy evidenced by phylogenetic analysis. Journal of Clinical Virology 2013, 57:263-266.
29. Delarocque-Astagneau E., Pillonel J., De Valk H., et al. An incident case-control study of modes of hepatitis C virus transmission in France. Annals of Epidemiology 2007, 17:755-762.
30. Ciancio A., Manzini P., Castagno F., et al. Digestive endoscopy is not a major risk factor for transmitting hepatitis C virus. Annals of Internal Medicine 2005, 142:903-909.
31. Chanzy B., Duc-Bin D.L., Rousset B., et al. Effectiveness of a manual disinfection procedure in eliminating hepatitis C virus from experimentally contaminated endoscopes. Gastrointestinal Endoscopy 1999, 50:147-151.
32. Sauné K., Kamar N., Miédougé M., et al. Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrology, Dialysis, Transplantation 2011, 26:2309-2316.
33. Jadoul M., Cornu C., van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney International 1998, 53:1022-1025.
34. Jadoul M., Poignet J.L., Geddes C. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrology, Dialysis, Transplantation 2004, 19:904-909.
35. Spada E., Abbate I., Sicurezza E., et al. Molecular epidemiology of a hepatitis C virus outbreak in a hemodialysis unit in Italy. Journal of Medical Virology 2008, 80:261-267.
36. Kidney Disease: Improving Global Outcomes (KDIGO) KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney International. Supplement 2008,S1-S99.
37. Fabrizi F., Messa P., Martin P. Transmission of hepatitis C virus infection in hemodialysis: current concepts. International Journal of Artificial Organs 2008, 31:1004-1016.
38. Girou E., Chevaliez S., Challine D., et al. Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit. Clinical Infectious Diseases 2008, 47:627-633.
39. Doerrbecker J., Friesland M., Ciesek S., et al. Inactivation and survival of hepatitis C virus on inanimate surfaces. Journal of Infectious Diseases 2011, 204:1830-1838.
40. Ciesek S., Friesland M., Steinmann J., et al. How stable is the hepatitis C virus (HCV)? Environmental stability of HCV and its susceptibility to chemical biocides. Journal of Infectious Diseases 2010, 201:1859-1866.
41. Degenhardt L., Whiteford H.A., Ferrari A.J., et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1564-1574.
42. Hope V.D., Eramova I., Capurro D., et al. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiology and Infection 2014, 142:270-286.
43. Hagan H., Thiede H., Weiss N.S., et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health 2001, 91:42-46.
44. Hurley S.F., Jolley D.J., Kaldor J.M. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet 1997, 349:1797-1800.
45. Wandeler G., Gsponer T., Bregenzer A., et al. Hepatitis C virus infections in the Swiss HIV cohort Study: a rapidly evolving epidemic. Clinical Infectious Diseases 2012, 55:1408-1416.
46. Judd A., Hickman M., Jones S., et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. British Medical Journal 2005, 330:24-25.
47. Nelson P.K., Mathers B.M., Cowie B., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378:571-583.
48. Aceijas C., Hickman M., Donoghoe M.C., et al. Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia. Addiction 2007, 102:1244-1250.
49. Demetriou V.L., van de Vijver D.A., Hezka J., et al. Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus. Journal of Medical Virology 2010, 82:263-270.
50. Reimer J., Lorenzen J., Baetz B., et al. Multiple viral hepatitis in injection drug users and associated risk factors. Journal of Gastroenterology and Hepatology 2007, 22:80-85.
51. Camoni L., Regine V., Salfa M.C., et al. Continued high prevalence of HIV HBV and HCV among injecting and noninjecting drug users in Italy. Annali dell'Istituto Superiore di Sanità 2010, 46:59-65.
52. Paintsil E., Verevochkin S.V., Dukhovlinova E., et al. Hepatitis C virus infection among drug injectors in St Petersburg Russia: social and molecular epidemiology of an endemic infection. Addiction 2009, 104:1881-1890.
53. Taylor L.E., Swan T., Mayer K.H. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clinical Infectious Diseases 2012, 55(Suppl. 1):S33-S42.
54. Thein H.H., Yi Q., Dore G.J., et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008, 22:1979-1991.
55. Amin J., Law M.G., Bartlett M., et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006, 368:938-945.
56. Prasad L., Spicher V.M., Negro F., et al. Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study. Journal of Viral Hepatitis 2009, 16:644-649.
57. Martin N.K., Hickman M., Hutchinson S.J., et al. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clinical Infectious Diseases 2013, 57(Suppl. 2):S39-S45.
58. Bruggmann P. Treatment as prevention: the breaking of taboos is required in the fight against hepatitis C among people who inject drugs. Hepatology 2013, 58:1523-1525.
59. http://ecdc.europa.eu/en/publications/Publications/TER_100914_Hep_B_C%20_EU_neighbourhood.pdf.
60. Akinci A., Bilgin Y., Erkal M.Z., et al. Hepatitis B and C virus serology in Turks living in Germany - a comparison of Turkey and Germany in view of migration. Postgraduate course at the European association for the study of the liver 1998.
61. Hüppe D., Zehnter E., Mauss S., et al. Epidemiology of chronic hepatitis C in Germany - an analysis of 10,326 patients in hepatitis centres and outpatient units. Zeitschrift fur Gastroenterologie 2008, 46:34-44.
62. Federal Statistical Office State & society - Population by immigrant background 2013, Available at:. https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/MigrationIntegration/Migrationshintergrund/Tabellen/MigrationshintergrundDoppelstaatler.html.
63. Federal Statistical Office State & society-Population by immigrant background 2013, Available at:. https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/MigrationIntegration/Migrationshintergrund/Tabellen/MigrationshintergrundDoppelstaatler.html.
64. Terrault N.A., Dodge J.L., Murphy E.L., et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology 2013, 57:881-889.
65. Piazza M., Sagliocca L., Tosone G., et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Archives of Internal Medicine 1997, 157:1537-1544.
66. Varan A.K., Mercer D.W., Stein M.S., et al. Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. Public Health Reports 2014, 129:187-195.
67. Saiz de la Hoya P., Marco A., García-Guerrero J., et al. Hepatitis C and B prevalence in Spanish prisons. European Journal of Clinical Microbiology and Infectious Diseases 2011, 30:857-862.
68. Brant L.J., Hurrelle M., Balogun M.A., et al. Where are people being tested for anti-HCV in England? Results from sentinel laboratory surveillance. Journal of Viral Hepatitis 2008, 15:729-739.
69. Almasio P.L., Babudieri S., Barbarini G., et al. Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). Digestive and Liver Disease 2011, 43:589-595.
70. Semaille C., Le Strat Y., Chiron E., et al. Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy. Euro Surveillance 2013, 18.
71. Sagnelli E., Starnini G., Sagnelli C., et al. Blood borne viral infections, sexually transmitted diseases and latent tuberculosis in Italian prisons: a preliminary report of a large multicenter study. European Review for Medical and Pharmacological Sciences 2012, 16:2142-2146.
72. Horne J.A., Clements A.J., Drennan P., et al. Screening for hepatitis C virus in the Dartmoor prison population: an observational study. Journal of Public Health 2004, 26:372-375.
73. Khaw F.M., Stobbart L., Murtagh M.J. 'I just keep thinking I haven't got it because I'm not yellow': a qualitative study of the factors that influence the uptake of Hepatitis C testing by prisoners. BMC Public Health 2007, 7:98.
74. Rotily M., Weilandt C., Bird S.M., et al. Surveillance of HIV infection and related risk behaviour in European prisons. A multicentre pilot study. European Journal of Public Health 2001, 11:243-250.
75. Vescio M.F., Longo B., Babudieri S., et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. Journal of Epidemiology and Community Health 2008, 62:305-313.
76. Long J., Allwright S., Barry J., et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: a national cross sectional survey. British Medical Journal 2001, 323:1209-1213.
77. Allwright S., Bradley F., Long J., et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. British Medical Journal 2000, 321:78-82.
78. Martín Sánchez V., Ferrer Castro V., Pallas Álvarez J.R., et al. Seroprevalence of hepatitis C virus infection at the time of entry to prison in the prison population in the north-east of Spain. Revista Española de de Salud Pública 1998, 72:43-51.
79. Weild A.R., Gill O.N., Bennett D., et al. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. Communicable Disease and Public Health 2000, 3:121-126.
80. Pallás J.R., Fariñas-Alvarez C., Prieto D., et al. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. European Journal of Epidemiology 1999, 15:699-704.
81. Dolan K., Rutter S., Wodak A.D. Prison-based syringe exchange programmes: a review of international research and development. Addiction 2003, 98:153-158.
82. Skipper C., Guy J.M., Parkes J., et al. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut 2003, 52:1500-1504.
83. de Juan J., Faraco I., Saiz de la Hoya P., et al. Reasons for not initiating HCV treatment in prison: a sub-analysis of the EPIBAND study. Revista Española de Sanidad Penitenciaria 2011, 13:44-51.
84. Saiz de la Hoya P., Portilla J., Marco A., et al. Directly observed therapy for chronic hepatitis C: a randomized clinical trial in the prison setting. Gastroenterología y Hepatología 2014, [Epub ahead of print].
85. Marco Mouriño A., da Silva Morán A., Ortiz Seuma J., et al. Predictors of adherence to treatment of chronic hepatitis C in drug-dependent inmate patients in four prisons in Barcelona, Spain. Revista Española de de Salud Pública 2010, 84:423-431.
86. Marco A., Esteban J.I., Solé C., et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. Journal of Hepatology 2013, 59:45-51.
87. Wedemeyer H., Duberg A.S., Buti M., et al. Strategies to manage hepatitis C virus (HCV) disease burden. Journal of Viral Hepatitis 2014, 21(Suppl. 1):60-89.
88. Smith B.D., Morgan R.L., Beckett G.A., et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR - Recommendations and Reports 2012, 61:1-32.
89. McGarry L.J., Pawar V.S., Panchmatia H.R., et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012, 55:1344-1355.